Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Share-based Compensation: 2020-2024

Historic Share-based Compensation for Candel Therapeutics (CADL) over the last 5 years, with Dec 2024 value amounting to $5.3 million.

  • Candel Therapeutics' Share-based Compensation rose 48.11% to $939,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $3.1 million, marking a year-over-year increase of 33.98%. This contributed to the annual value of $5.3 million for FY2024, which is 71.85% up from last year.
  • According to the latest figures from FY2024, Candel Therapeutics' Share-based Compensation is $5.3 million, which was up 71.85% from $3.1 million recorded in FY2023.
  • In the past 5 years, Candel Therapeutics' Share-based Compensation ranged from a high of $5.3 million in FY2024 and a low of $2.1 million during FY2020.
  • In the last 3 years, Candel Therapeutics' Share-based Compensation had a median value of $3.1 million in 2023 and averaged $3.6 million.
  • As far as peak fluctuations go, Candel Therapeutics' Share-based Compensation decreased by 22.14% in 2022, and later spiked by 71.85% in 2024.
  • Over the past 5 years, Candel Therapeutics' Share-based Compensation (Yearly) stood at $2.1 million in 2020, then surged by 40.63% to $3.0 million in 2021, then decreased by 22.14% to $2.3 million in 2022, then soared by 33.98% to $3.1 million in 2023, then soared by 71.85% to $5.3 million in 2024.